Stock VLS VITA LIFE SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vita Life Sciences Limited

Equities

VLS

AU000000VLS8

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 08:23:30 2024-05-13 pm EDT 		5-day change 1st Jan Change
2.08 AUD -0.48% Intraday chart for Vita Life Sciences Limited -9.17% +16.85%
Feb. 26 Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 53.2 37.24 54.08 104.9 76.59 95.85
Enterprise Value (EV) 1 44.33 29.11 41.68 89.34 61.51 71.61
P/E ratio 21.8 x 11.7 x 8.64 x 12.2 x 10.3 x 10.7 x
Yield 3.87% 5.6% 4.25% 3.03% 4.43% 5.06%
Capitalization / Revenue 1.29 x 0.88 x 1.16 x 1.84 x 1.15 x 1.29 x
EV / Revenue 1.08 x 0.69 x 0.9 x 1.56 x 0.92 x 0.97 x
EV / EBITDA 6.86 x 6.65 x 5.34 x 7.95 x 5.6 x 5.92 x
EV / FCF 5.87 x 13.9 x 6.2 x 19.2 x 32.2 x 6.41 x
FCF Yield 17% 7.19% 16.1% 5.22% 3.1% 15.6%
Price to Book 2.38 x 1.65 x 2.19 x 3.41 x 2.09 x 2.31 x
Nbr of stocks (in thousands) 54,842 55,587 54,083 55,188 56,527 53,850
Reference price 2 0.9700 0.6700 1.000 1.900 1.355 1.780
Announcement Date 3/27/19 3/26/20 3/25/21 3/24/22 3/24/23 3/18/24
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 41.15 42.45 46.48 57.1 66.89 74.16
EBITDA 1 6.464 4.38 7.809 11.24 10.98 12.1
EBIT 1 6.076 4.107 7.569 11.02 10.73 11.87
Operating Margin 14.77% 9.67% 16.28% 19.29% 16.04% 16%
Earnings before Tax (EBT) 1 4.33 4.428 8.158 11.2 10.74 12.45
Net income 1 2.439 3.136 6.094 8.292 7.084 9.08
Net margin 5.93% 7.39% 13.11% 14.52% 10.59% 12.24%
EPS 2 0.0444 0.0573 0.1158 0.1561 0.1312 0.1660
Free Cash Flow 1 7.556 2.094 6.723 4.665 1.908 11.17
FCF margin 18.36% 4.93% 14.46% 8.17% 2.85% 15.06%
FCF Conversion (EBITDA) 116.89% 47.8% 86.1% 41.49% 17.38% 92.35%
FCF Conversion (Net income) 309.79% 66.76% 110.33% 56.26% 26.94% 123.01%
Dividend per Share 2 0.0375 0.0375 0.0425 0.0575 0.0600 0.0900
Announcement Date 3/27/19 3/26/20 3/25/21 3/24/22 3/24/23 3/18/24
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 8.87 8.13 12.4 15.5 15.1 24.2
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 7.56 2.09 6.72 4.66 1.91 11.2
ROE (net income / shareholders' equity) 10.3% 13.8% 25% 30.1% 21.9% 22.7%
ROA (Net income/ Total Assets) 11.1% 7.11% 12.5% 16.3% 13.8% 13.3%
Assets 1 22.05 44.12 48.71 50.81 51.27 68.32
Book Value Per Share 2 0.4100 0.4100 0.4600 0.5600 0.6500 0.7700
Cash Flow per Share 2 0.2000 0.1900 0.2700 0.2900 0.2800 0.4400
Capex 1 0.37 0.05 0.09 0.16 0.14 0.66
Capex / Sales 0.9% 0.13% 0.19% 0.27% 0.21% 0.89%
Announcement Date 3/27/19 3/26/20 3/25/21 3/24/22 3/24/23 3/18/24
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
VITA LIFE SCIENCES LIMITED Stock Vita Life Sciences Limited
+16.85% 76.97M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.99% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.51% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.18% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.08% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 240B
NOVARTIS AG Stock Novartis AG
+10.16% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 203B
AMGEN INC. Stock Amgen Inc.
+8.34% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VLS Stock
  4. Financials Vita Life Sciences Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW